Identification of a distinct luminal subgroup diagnosing and stratifying early stage prostate cancer by tissue-based single-cell RNA sequencing
-
Published:2020-10-08
Issue:1
Volume:19
Page:
-
ISSN:1476-4598
-
Container-title:Molecular Cancer
-
language:en
-
Short-container-title:Mol Cancer
Author:
Ma Xiaoshi, Guo Jinan, Liu Kaisheng, Chen Lipeng, Liu Dale, Dong Shaowei, Xia Jinquan, Long Qiaoyun, Yue Yongjian, Zhao Pan, Hu Fengyan, Xiao Zhangang, Pan Xinghua, Xiao Kefeng, Cheng Zhiqiang, Ke Zunfu, Chen Zhe-ShengORCID, Zou Chang
Abstract
Abstract
Background
The highly intra-tumoral heterogeneity and complex cell origination of prostate cancer greatly limits the utility of traditional bulk RNA sequencing in finding better biomarker for disease diagnosis and stratification. Tissue specimens based single-cell RNA sequencing holds great promise for identification of novel biomarkers. However, this technique has yet been used in the study of prostate cancer heterogeneity.
Methods
Cell types and the corresponding marker genes were identified by single-cell RNA sequencing. Malignant states of different clusters were evaluated by copy number variation analysis and differentially expressed genes of pseudo-bulks sequencing. Diagnosis and stratification of prostate cancer was estimated by receiver operating characteristic curves of marker genes. Expression characteristics of marker genes were verified by immunostaining.
Results
Fifteen cell groups including three luminal clusters with different expression profiles were identified in prostate cancer tissues. The luminal cluster with the highest copy number variation level and marker genes enriched in prostate cancer-related metabolic processes was considered the malignant cluster. This cluster contained a distinct subgroup with high expression level of prostate cancer biomarkers and a strong distinguishing ability of normal and cancerous prostates across different pathology grading. In addition, we identified another marker gene, Hepsin (HPN), with a 0.930 area under the curve score distinguishing normal tissue from prostate cancer lesion. This finding was further validated by immunostaining of HPN in prostate cancer tissue array.
Conclusion
Our findings provide a valuable resource for interpreting tumor heterogeneity in prostate cancer, and a novel candidate marker for prostate cancer management.
Funder
Natural Science Foundation of Guangdong Province the Science and Technology Foundation of Shenzhen Applied Basic Research Foundation of Yunnan Province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Medicine
Reference50 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, A. J. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. 2. Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, Davis M, Peters TJ, Turner EL, Martin RM, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate Cancer. N Engl J Med. 2016;375:1415–24. 3. Komura K, Sweeney CJ, Inamoto T, Ibuki N, Azuma H, Kantoff PW. Current treatment strategies for advanced prostate cancer. Int J Urol. 2018;25:220–31. 4. Candefjord S, Ramser K, Lindahl OA. Technologies for localization and diagnosis of prostate cancer. J Med Eng Technol. 2009;33:585–603. 5. Pathak H, Gupta M, Kumar D, Lakhe V, Rahangdale P, Fulari N. Prostate Cancer: PSA and other diagnostic modalities for the early diagnosis. Indian Pract. 2014;67:436–40.
Cited by
64 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|